opinion of the investigator, will make it unlikely that the subject will comply with the 5 protocol. 
QFT assay 17
The QFT assay was conducted according to the manufacturer's instructions, with 18 implementation of more stringent parameters unless otherwise stated. Briefly, 1mL of blood 19 was collected in each QFT tube and mixed by 10 manual inversions and 5 minutes on a tube 20 rotator, incubated at 37°C within 2 hours from phlebotomy for 16 to 20 hours, and plasma 21 was harvested without further delay. Supplementary quality control criteria, in addition to the 22 manufacturer's algorithm, were implemented as described 6 . 23 24
PBMC Intracellular Cytokine Staining Assay 25
Peripheral blood mononuclear cells (PBMC) were isolated from blood collected on D0 and 26 D70 from participants in the safety and immunogenicity cohort. PBMCs were cryopreserved 27 and shipped to Aeras, Cape Town, South Africa where a 13-colour intracellular cytokine 28 staining (ICS) assay was performed 7 . PBMCs were thawed, suspended in R10 medium, and 29 rested overnight. R10 medium is composed of 10% FBS (GemCell 100-500, triple filtered or 30 equivalent), 55µM ßME (Gibco BRL 21985-023 or equivalent), 10 mM HEPES (Gibco BRL 31 15630-080 or equivalent), 2mM L-glutamine (Gibco BRL 25030-081 or equivalent), and 1 x 32 the Guava easyCyte Flow Cytometer; stimulation was only performed on samples with at 1 least 70% viability. Analysis Plan (SAP), which was finalized prior to database lock. 32
The final analyses associated with the primary and secondary endpoints remained entirely 33 unchanged from the primary analysis. Some of the exploratory endpoints that had not been 34 included within the primary analysis, including the evaluation of alternative QFT thresholds 35 and the evaluation of sustained QFT conversions and late reversions at EoS, were proposedby blinded members of the study team prior to database lock. While members of the JSC 1 approved the final SAP, they were not involved in the selection of alternative QFT thresholds 2 or the determination of methodology to evaluate trends in QFT over time. 3 
4
The study was not powered to assess vaccine efficacy for prevention of TB disease. Based 5 on studies in this population [8] [9] [10] we would expect to observe between 1 and 13 TB incident 6 cases 95% of the time. 7 8 Unless otherwise indicated, SAS 9.4 (SAS Institute, Cary, NC) was used for data analysis, 9 and the analyses were completed by Quintiles (now called IQVIA). 10 11
Efficacy 12
Prior to database lock and trial unblinding, we chose to prioritize the modified intent-to-treat 13 analyses over the per-protocol analyses to be more reflective of a potential vaccine effect 14 from real-world use rather than in a more idealistic clinical trial setting. 15
The trial's primary efficacy endpoint, time to first QFT conversion after D84 using the 16 manufacturer's recommended threshold of IFNg ≥ 0.35 IU/mL, was evaluated using a one-17 sided log-rank statistic to compare H4:IC31 versus placebo and BCG versus placebo without 18 adjustment for multiplicity. The rationale for not adjusting for multiplicity to control the Type 1 19 error rate over the two tests is that the tests pertain to efficacy assessments of two unrelated 20 vaccines. If these two evaluations were performed in two separate trials then no adjustment 21 for multiplicity would be made. Thus, one should not be compelled to adjust for this 22 multiplicity simply because the two evaluations are performed administratively in a single 23
trial. 24
Estimates of vaccine efficacy were based on the hazard ratio estimate from a Cox 25 regression model. Participants who did not experience a primary endpoint were censored at 26 the date of their last available, non-positive QFT result; indeterminate results were treated as 27 negative results. The log-rank statistic was evaluated using a one-sided test to reflect the 28 way in which the trial was originally designed and powered, and two-sided 80% and 95% CI 29 of vaccine efficacy are reported. Sensitivity analyses associated with the primary efficacy 30 endpoint, including time to first QFT conversion after D0 (i.e., including conversions detected 31 on D84) and time to event using interval-censoring, were also evaluated. 32
33
The secondary efficacy endpoint was defined as sustained QFT conversion without a≥ 0.35 IU/mL maintained at 3 and 6 months post-initial conversion). This endpoint was 1 evaluated in the same manner as described above for the primary efficacy endpoint. 2 3 Several exploratory efficacy analyses further evaluated the vaccine ability to prevent or 4 modulate infection: 5
• Median QFT levels at the time of initial conversion were compared between 6 treatment groups using Mann-Whitney-Wilcoxon tests. 7
• Time to QFT reversion among those participants who converted was evaluated using 8 a log-rank test. 9
• Time to first QFT conversion among those who ever reverted was evaluated using a 10 log-rank test. 11
• Time to end-of-study sustained conversion (as opposed to sustained conversion for 6 12 months) was evaluated in the same manner as the secondary efficacy endpoint 13 (described above). 14 15
The proportion of participants classified as converters according to alternative QFT 16 thresholds (i.e., ≥0.2IU/mL; <0.2IU/mL at any time point prior to conversion and >0.7IU/mL 17 at any time point post-D84; >0.7IU/mL; >4.0IU/mL) were compared across study arms. QFT conversion and reversion rates at the end of the 24-month study follow-up period. 25
Trends in QFT status were analysed similarly to the alternative QFT thresholds (i.e., based 26 on a conditional binomial distribution and using the Clopper-Pearson method with mid-p 27 correction for 80% and 95% CI) and were compared between treatment groups based on 28
Pearson's Chi-square for the following endpoints of interest: 29
• Participants who were QFT negative at Month 24 or the Month 24 call-back visit. 30
• Participants who never converted or who converted without sustained conversion. 31
• Participants who never converted or who converted with reversion and had non-32 positive 6-month post-initial-conversion QFT values.
Note: Some analyses were based on subsets of participants determined by a post-1 randomization event such as reversion post-conversion, and some involved participants 2 who experienced differential follow-up. These types of analyses have the potential to be 3 biased, therefore they were not prioritized. cellulitis (n=1); subcutaneous abscess (n=1); near drowning (n=1); completed suicide (n=1); eclampsia (n=1) and premature rupture of membranes (n=1) in the Placebo arm (subtotal n=7); pyelonephritis (n=2); viral meningitis (n=1); road traffic accident (n=1) and intentional selfinjury (n=1) in the H4:IC31 arm (subtotal n=5); and gastroenteritis (n=2); chest injury (n=1); thermal burn (n=1); intentional self-injury (n=1); suicide attempt (n=1) and small intestinal obstruction (n=1) in the BCG arm (subtotal n=7) (total n=19). *p=0.0003 calculated by two by three Chi Square test. 
